ReShape Lifesciences Inc
As of August 14, 2025, ReShape Lifesciences Inc. was acquired by Vyome Therapeutics Inc., in a reverse merger transaction. ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling… Read more
Market Cap & Net Worth: ReShape Lifesciences Inc (RSLS)
ReShape Lifesciences Inc (NASDAQ:RSLS) has a market capitalization of $9.35 Million ($9.35 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #33127 globally and #10836 in its home market, demonstrating a 51.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ReShape Lifesciences Inc's stock price $3.92 by its total outstanding shares 2385960 (2.39 Million).
ReShape Lifesciences Inc Market Cap History: 2016 to 2025
ReShape Lifesciences Inc's market capitalization history from 2016 to 2025. Data shows change from $612.36 Billion to $9.35 Million (-73.05% CAGR).
Index Memberships
ReShape Lifesciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #842 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2657 of 3165 |
Weight: ReShape Lifesciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ReShape Lifesciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ReShape Lifesciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.33x
ReShape Lifesciences Inc's market cap is 1.33 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $612.36 Billion | $786.66K | -$23.36 Million | 778426.05x | N/A |
| 2017 | $457.36 Billion | $1.29 Million | -$33.82 Million | 355330.19x | N/A |
| 2018 | $143.23 Billion | $606.71K | -$81.15 Million | 236075.19x | N/A |
| 2019 | $13.15 Billion | $15.09 Million | -$74.21 Million | 871.27x | N/A |
| 2020 | $10.38 Billion | $11.30 Million | -$21.63 Million | 918.57x | N/A |
| 2021 | $11.35 Billion | $13.60 Million | -$61.93 Million | 834.38x | N/A |
| 2022 | $932.72 Million | $11.24 Million | -$46.21 Million | 82.98x | N/A |
| 2023 | $34.55 Million | $8.68 Million | -$11.39 Million | 3.98x | N/A |
| 2024 | $10.67 Million | $8.01 Million | -$7.13 Million | 1.33x | N/A |
Competitor Companies of RSLS by Market Capitalization
Companies near ReShape Lifesciences Inc in the global market cap rankings as of March 19, 2026.
Key companies related to ReShape Lifesciences Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
ReShape Lifesciences Inc Historical Marketcap From 2016 to 2025
Between 2016 and today, ReShape Lifesciences Inc's market cap moved from $612.36 Billion to $ 9.35 Million, with a yearly change of -73.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $9.35 Million | -12.31% |
| 2024 | $10.67 Million | -69.13% |
| 2023 | $34.55 Million | -96.30% |
| 2022 | $932.72 Million | -91.78% |
| 2021 | $11.35 Billion | +9.33% |
| 2020 | $10.38 Billion | -21.05% |
| 2019 | $13.15 Billion | -90.82% |
| 2018 | $143.23 Billion | -68.68% |
| 2017 | $457.36 Billion | -25.31% |
| 2016 | $612.36 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ReShape Lifesciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.35 Million USD |
| MoneyControl | $9.35 Million USD |
| MarketWatch | $9.35 Million USD |
| marketcap.company | $9.35 Million USD |
| Reuters | $9.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.